Press

Wellbeing Digital to Participate at this Years’ Wonderland Miami Conference

Oct 26 • 2 min read

Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO, will participate at this years’ Wonderland Miami Conference taking place on November 3 to November…

Reunion Neuroscience Opens the Market

Oct 26 • 1 min read

Greg Mayes, President & Chief Executive Officer; Nathan Bryson, Chief Science Officer, and other members of the Reunion Neuroscience Inc. (TSX: REUN) management team joined Karoline Hunter, Head, Company Services, Toronto Stock Exchange, to celebrate the Company’s new listing on Toronto Stock Exchange and open the market. Watch the video here Previously the drug development division of Field…

Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference

Oct 26 • 3 min read

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that James Kuo, M.D. M.B.A, Vice President of R&D, will speak as a panelist at Wonderland: Miami, the largest business gathering in the psychedelic medicine sector. Silo Pharma is a sponsor of the three-day conference being…

Aion Therapeutic Provides Default Status Update

Oct 25 • 2 min read

Aion Therapeutic Inc. (CSE: AION) announces that further to its press releases of September 13, 2022, September 26, 2022 and October 11, 2022, it is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 – Cease Trade Orders for Continuous Disclosure Defaults (“NP 12-203”). On August 30, 2022,…

Core One Labs Takes Next Steps to Prepare for Potential Takeover Opportunities

Oct 25 • 3 min read

Core One Labs Inc. (CSE:COOL | OTCQB:CLABF | Frankfurt:LD6, WKN:A3CSSU) is pleased to announce, as a follow up to the Company’s press release dated March 20, 2022, wherein the Company announced that it was actively working to investigate investment and potential takeover opportunities by strategic psychedelics or pharmaceutical companies, that the Company’s Board of Directors is…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435